Recent Updates
Recently added Catalysts
WAT Positive Sentiment

Waters Launches New Walk-up Solutions that Further Simplify the Analysis of Biologic Drug Product and Cell Culture Media News Summary: Updated Waters™ OneLab™ software creates new, easy-to-use walk-up solutions integrating Waters BioAccord™ LC-MS system and Andrew+™...

Key Takeaway: Waters Corporation has launched new bioprocess walk-up solutions designed to simplify the analysis of biologic drug products and cell culture media. The solutions leverage updated OneLab software and the BioAccord LC-MS system, allowing bioprocess engineers to perform analyses directly from bioreactor samples. This innovation can significantly reduce development timelines and improve process understanding, leading to more efficient manufacturing. The solutions are now available worldwide and support seamless data transfer from Sartorius Ambr Multi-Parallel Bioreactors.
Price reaction · baseline $263.3 (2023-09-11 close) · hit after-hours · clean, no other WAT news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • New walk-up solutions simplify biologic sample preparation and analysis.
  • Can accelerate upstream bioprocess development by up to six weeks.
  • Integrated software and robotics reduce human error and costs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~19 mo
Low dilution risk
Lead asset
CYTALUX preoperatively
Phase 2 · Esophageal Cancer

Full Press Release Details

MILFORD, Mass. , Sept. 12, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announced new bioprocess walk-up solutions designed to further simplify biologic sample prep and analysis. By eliminating the need to send bioreactor samples to a central laboratory for analysis, the new solutions make it even easier to accelerate upstream bioprocess development by up to six weeks over traditional methods. i Enabled by updates to Waters OneLab™ laboratory automation software and new pre-developed analytical workflows, the combination allows bioprocess engineers to capture high-quality bioprocess and drug product data with just a few clicks.
Waters announced new bioprocess walk-up solutions that further simplify sample prep and analysis from any bioreactor.
Waters combines its BioAccord™ liquid chromatography-mass spectrometry (LC-MS) system and the Waters Andrew + ™ robot connected via new protocols in OneLab software to create fully integrated and easy-to-use bioprocess walk-up solutions. It is designed to enable less experienced LC-MS users to acquire critical quality attribute (CQA) data for analysis of drug product and cell culture media. Capturing data directly at the bioproduction laboratory can help bioprocess engineers improve process understanding, leading to more robust manufacturing processes and accelerated development timelines.
"Waters has made it easier for bioprocess engineers to access rich analytical and CQA data straight from the bioreactor," said Jon Pratt , Senior Vice President, Waters Division. "The integrated combination of software, automation, and pre-developed LC-MS analytical workflows eliminates manual steps previously required for sample preparation, injection, data acquisition, and data transfer. The impact is to reduce human errors and enable process improvements that can ultimately translate to lower downstream costs for manufacturing and drug product prices for patients."
Updated OneLab software is at the heart of the Waters bioprocess walk-up solutions. It incorporates new pre-developed analytical workflows that further simplify the user experience for routine product and process quality measurements of at-line samples from any bioreactor system.
For users of Sartorius Ambr ® Multi-Parallel Bioreactors, Waters also provides a software interface to the BioAccord LC-MS system for seamless data transfer. The software interface supports both the Sartorius Ambr ® 15 and Ambr ® 250 High Throughput Bioreactor Systems.
Waters bioprocess walk-up solutions are now available worldwide through Waters.
Additional Resources
About Waters Corporation ( www.waters.com )
Waters Corporation (NYSE: WAT ), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, OneLab, BioAccord, and Andrew+ are trademarks of Waters Corporation. Ambr is a registered trademark of Sartorius.
Kevin Kempskie Senior PR Director, Corporate Communications Waters Corporation +1.508.482.2814 [email protected]
i Bioprocess engineers typically wait 2-6 weeks for the return of LC-MS sample results from central or outsourced analytical labs according to customers surveyed by Waters; see further detail in Evolving Analytics in the Upstream Lab by Using the Power of LC-MS , a Waters/Sartorius webinar, Nov. 30, 2021

Frequently Asked Questions

What are Waters' new bioprocess walk-up solutions?

They simplify biologic sample preparation and analysis, eliminating central lab needs.

How do these solutions accelerate bioprocess development?

They reduce development timelines by up to six weeks compared to traditional methods.

What technology supports the bioprocess walk-up solutions?

They integrate Waters' BioAccord LC-MS system and Andrew+ robot with OneLab software.

Who can benefit from the new bioprocess solutions?

Less experienced LC-MS users can easily obtain critical quality attribute data.

Are these solutions available globally?

Yes, Waters bioprocess walk-up solutions are available worldwide.

Last updated: Sep 12, 2023